| User's Publication |
|
21716
Zhen Y, Liu K, Shi L, Shah S, Xu Q, Ellis H, Balasooriya ER, Kreuzer J, Morris R, Baldwin AS, Juric D, Haas W, Bardeesy N.
FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma.
Nat Commun
2024
15(1):3805
PubMed ID: 38714664
DOI: 10.1038/s41467-024-47514-y
|
|
21734
Luk IS, Bridgwater CM, Yu A, Boila LD, Yáñez-Bartolomé M, Lampano AE, Hulahan TS, Boukhali M, Kathiresan M, Macarulla T, Kenerson HL, Yamamoto N, Sokolov D, Engstrom IA, Sullivan LB, Lampe PD, Cooper JA, Yeung RS, Tian TV, Haas W, Saha SK, Kugel S.
SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.
Sci Transl Med
2024
16(747):eadj7685
PubMed ID: 38748774
DOI: 10.1126/scitranslmed.adj7685
|
|
21755
Oh J, Kirsh C, Hsin JP, Radecki KC, Zampieri A, Manry D, Ando Y, Miller S, Chan J, McLeod E, Cunningham KM, Wong LM, Xu H, Kamb A.
NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens.
iScience
2024
27(6):109913
PubMed ID: 38799557
DOI: 10.1016/j.isci.2024.109913
|
|
21815
Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS.
NAPRT silencing in FH-deficient renal cell carcinoma confers therapeutic vulnerabilities via NAD+ depletion.
Mol Cancer Res
2024
PubMed ID: 38949523
DOI: 10.1158/1541-7786.MCR-23-1003
|
|
20980
Takahashi M, Tsuchikawa T, Hiwasa T, Nakamura T, Hontani K, Kushibiki T, Inoko K, Takano H, Hatanaka Y, Matsushita K, Matsubara H, Hoshino T, Ohtsuka M, Shimada H, Tanaka K, Nakanishi Y, Asano T, Noji T, Okamura K, Shichinohe T, Hirano S.
Identification of antibody against wingless‑type MMTV integration site family member 7B as a biliary cancer tumor marker.
Oncol Rep
2023
49(2)
PubMed ID: 36562381
DOI: 10.3892/or.2022.8471
|
|
20994
Deshmukh D, Hsu YF, Chiu CC, Jadhao M, Hsu SCN, Hu SY, Yang SH, Liu W.
Antiangiogenic potential of Lepista nuda extract suppressing MAPK/p38 signaling-mediated developmental angiogenesis in zebrafish and HUVECs.
Biomed Pharmacother
2023
159:114219
PubMed ID: 36621144
DOI: 10.1016/j.biopha.2023.114219
|
|
21103
Shi L, Shen W, Davis MI, Kong K, Vu P, Saha SK, Adil R, Kreuzer J, Egan R, Lee TD, Greninger P, Shrimp JH, Zhao W, Wei TY, Zhou M, Eccleston J, Sussman J, Manocha U, Weerasekara V, Kondo H, Vijay V, Wu MJ, Kearney SE, Ho J, McClanaghan J, Murchie E, Crowther GS, Patnaik S, Boxer MB, Shen M, Ting DT, Kim WY, Stanger BZ, Deshpande V, Ferrone CR, Benes CH, Haas W, Hall MD, Bardeesy N.
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers.
Nat Cancer
2023
PubMed ID: 36914816
DOI: 10.1038/s43018-023-00523-0
|
|
21456
Toshida K, Itoh S, Iseda N, Izumi T, Yoshiya S, Toshima T, Ninomiya M, Iwasaki T, Oda Y, Yoshizumi T.
Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma.
Cancer Sci
2023
PubMed ID: 37878531
DOI: 10.1111/cas.15981
|
|
21553
Louis C, Ferlier T, Leroux R, Pineau R, Desoteux M, Papoutsoglou P, Leclerc D, Angenard G, Vaquero J, Macias RIR, Edeline J, Coulouarn C.
TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p.
JHEP Rep
2023
5(12):100900
PubMed ID: 38023605
DOI: 10.1016/j.jhepr.2023.100900
|
|
17559
Wu WS, Ling CH, Lee MC, Cheng CC, Chen RF, Lin CF, You RI, Chen YC.
Targeting Src-Hic-5 Signal Cascade for Preventing Migration of Cholangiocarcinoma Cell HuCCT
Biomedicines
2022
10(5):1022
PubMed ID: 35625759
DOI: 10.3390/biomedicines10051022
|
|
17715
Zhang L, Ma D, Li F, Qiu G, Sun D, Zeng Z.
Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance
Front Oncol
2022
12:871281
PubMed ID: 35965521
DOI: 10.3389/fonc.2022.871281
|
|
18223
Mancarella S, Serino G, Gigante I, Cigliano A, Ribback S, Sanese P, Grossi V, Simone C, Armentano R, Evert M, Calvisi DF, Giannelli G.
CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
J Exp Clin Cancer Res
2022
41(1):65
PubMed ID: 35172861
DOI: 10.1186/s13046-022-02283-8
|
|
18224
Sadahiro Y, Hitora Y, Kimura I, Hitora-Imamura N, Onodera R, Motoyama K, Tsukamoto S.
Colletofragarone A2 Inhibits Cancer Cell Growth In Vivo and Leads to the Degradation and Aggregation of Mutant p53
Chem Res Toxicol
2022
35(9):1598-1603
PubMed ID: 36027604
DOI: 10.1021/acs.chemrestox.2c00202
|
|
16108
Mohamed FEZ, Jalan R, Minogue S, Andreola F, Habtesion A, Hall A, Winstanley A, Damink SO, Malagó M, Davies N, Luong TV, Dhillon A, Mookerjee R, Dhar D, Al-Jehani RM.
Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development
Dig Dis Sci
2022
67(5):1806-1821
PubMed ID: 33939146
DOI: 10.1007/s10620-021-06973-9
|
|
16279
Seo HR, Nam AR, Bang JH, Oh KS, Kim JM, Yoon J, Kim TY, Oh DY.
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
Cancer Res Treat
2022
Aug 6
PubMed ID: 34352995
DOI: 10.4143/crt.2021.473
|
|
20601
Tessiri S, Techasen A, Kongpetch S, Namjan A, Loilome W, Chan-On W, Thanan R, Jusakul A.
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
PeerJ
2022
10:e12750
PubMed ID: 35070505
DOI: 10.7717/peerj.12750
|
|
20634
Yamamoto Y, Sugimoto A, Maruo K, Tsujio G, Sera T, Kushiyama S, Nishimura S, Kuroda K, Togano S, Eguchi S, Tanaka R, Kimura K, Amano R, Ohira M, Yashiro M.
CXCR2 signaling might have a tumor-suppressive role in patients with cholangiocarcinoma.
PLoS One
2022
17(4):e0266027
PubMed ID: 35377900
DOI: 10.1371/journal.pone.0266027
|
|
16513
Gundlach JP, Kerber J, Hendricks A, Bernsmeier A, Halske C, Röder C, Becker T, Röcken C, Braun F, Sebens S, Heits N.
Paracrine Interaction of Cholangiocellular Carcinoma with Cancer-Associated Fibroblasts and Schwann Cells Impact Cell Migration
J Clin Med
2022
11(10):2785
PubMed ID: 35628911
DOI: 10.3390/jcm11102785
|
|
20763
Tanaka R, Kimura K, Eguchi S, Ohira G, Tanaka S, Amano R, Tanaka H, Yashiro M, Ohira M, Kubo S.
Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line.
BMC Cancer
2022
22(1):748
PubMed ID: 35804329
DOI: 10.1186/s12885-022-09847-z
|
|
20772
Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T.
KRAS mutation in intrahepatic cholangiocarcinoma: linkage with metastasis-free survival and reduced E-cadherin expression.
Liver Int
2022
PubMed ID: 35833881
DOI: 10.1111/liv.15366
|
|
20794
Chen S, Nishi M, Morine Y, Yoshikawa K, Tokunaga T, Kashihara H, Takasu C, Wada Y, Yoshimoto T, Nakamoto A, Sakai T, Shimada M.
Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts.
Oncol Lett
2022
24(1):236
PubMed ID: 35720469
DOI: 10.3892/ol.2022.13356
|
|
20986
Rattanasinchai C, Navasumrit P, Ruchirawat M.
Elevated ITGA2 expression promotes collagen type I-induced clonogenic growth of intrahepatic cholangiocarcinoma.
Sci Rep
2022
12(1):22429
PubMed ID: 36575207
DOI: 10.1038/s41598-022-26747-1
|
|
21003
Leelawat S, Leelawat K, Yimsoo T, Wunnakup T, Monton C, Khamthong N, Madaka F, Maha A, Songsak T.
Antitumor Effects of Delta (9)-Tetrahydrocannabinol and Cannabinol on Cholangiocarcinoma Cells and Xenograft Mouse Models.
Evid Based Complement Alternat Med
2022
6477132
PubMed ID: 36452140
DOI: 10.1155/2022/6477132
|
|
21043
Wu WS, Chen RF, Cheng CC, Wei JL, Lin CF, You RI, Chen YC, Lee MC, Chen YC.
Suppressing of Src-Hic-5-JNK-AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma.
Pharmaceutics
2022
14(12)
PubMed ID: 36559193
DOI: 10.3390/pharmaceutics14122698
|
|
19225
Fukushi D, Shibuya-Takahashi R, Mochizuki M, Fujimori H, Kogure T, Sugai T, Iwai W, Wakui Y, Abue M, Murakami K, Nakamura Y, Yasuda J, Yamaguchi K, Sugamura K, Shibata C, Katayose Y, Satoh K, Tamai K.
BEX2 is required for maintaining dormant cancer stem cell in hepatocellular carcinoma
Cancer Sci
2021
112(11):4580-4592
PubMed ID: 34424582
DOI: 10.1111/cas.15115
|
|
13410
Saijoh S, Nakamura-Shima M, Shibuya-Takahashi R, Ito R, Sugawara A, Yamazaki T, Imai T, Asada Y, Matsuura K, Iwai W, Wakui Y, Abue M, Kawamura S, Katayose Y, Fujimori H, Mochizuki M, Yasuda J, Yamaguchi K, Sugamura K, Satoh K, Katori Y, Tamai K.
Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein.
Biochem Biophys Res Commun
2021
PubMed ID: 33412384
DOI: 10.1016/j.bbrc.2020.11.022
|
|
13485
Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N.
Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes
Cancer Sci
2021
112(2):828-838
PubMed ID: 33345417
DOI: 10.1111/cas.14780
|
|
20017
Rose S, Ezan F, Cuvellier M, Bruyère A, Legagneux V, Langouët S, Baffet G.
Generation of proliferating human adult hepatocytes using optimized 3D culture conditions.
Sci Rep
2021
11(1):515
PubMed ID: 33436872
DOI: 10.1038/s41598-020-80019-4
|
|
13539
Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK.
Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis
Dig Dis Sci
2021
66(4):1080-1089
PubMed ID: 32445050
DOI: 10.1007/s10620-020-06330-2
|
|
20163
Nam AR, Yoon J, Jin MH, Bang JH, Oh KS, Seo HR, Kim JM, Kim TY, Oh DY.
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
Cancer Lett
2021
516:38-47
PubMed ID: 34082024
DOI: 10.1016/j.canlet.2021.05.029
|
|
20178
Cen W, Li J, Tong C, Zhang W, Zhao Y, Lu B, Yu J.
Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2.
J Cancer
2021
12(12):3448-3457
PubMed ID: 33995623
DOI: 10.7150/jca.55627
|
|
20228
Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.
Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y.
Cancer Med
2021
PubMed ID: 34245137
DOI: 10.1002/cam4.4121
|
|
15516
Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T.
Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma
ancers (Basel)
2021
13(11):2804
PubMed ID: 34199886
DOI: 10.3390/cancers13112804
|
|
16106
Wang D, Xiong F, Wu G, Liu W, Wang B, Chen Y.
MiR-155-5p suppresses SOX1 to promote proliferation of cholangiocarcinoma via RAF/MEK/ERK pathway
Cancer Cell Int
2021
;21(1):656
PubMed ID: 34876142
DOI: 10.1186/s12935-021-02374-0
|
|
16761
Bai X, Zhang H, Zhou Y, Nagaoka K, Meng J, Ji C, Liu D, Dong X, Cao K, Mulla J, Cheng Z, Mueller W, Bay A, Hildebrand G, Lu S, Wallace J, Wands JR, Sun B, Huang CK.
Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1
Hepatology
2021
73(5):1747-1763
PubMed ID: 32740973
DOI: 10.1002/hep.31486
|
|
12007
Win Maung HM, Chan-On W, Kunkeaw N, Khaenam P.
Common transcriptional programs and the role of chemokine (C-C motif) ligand 20 (CCL20) in cell migration of cholangiocarcinoma.
EXCLI J
2020
PubMed ID: 32194362
DOI: 10.17179/excli2019-1893
|
|
12030
Yoshizawa N, Sugimoto K, Tameda M, Inagaki Y, Ikejiri M, Inoue H, Usui M, Ito M, Takei Y.
miR-3940-5p/miR-8069 ratio in urine exosomes is a novel diagnostic biomarker for pancreatic ductal adenocarcinoma.
Oncol Lett
2020
PubMed ID: 32218818
DOI: 10.3892/ol.2020.11357
|
|
12036
San TT, Khaenam P, Prachayasittikul V, Sripa B, Kunkeaw N, Chan-On W.
Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells.
Heliyon
2020
PubMed ID: 32051864
DOI: 10.1016/j.heliyon.2020.e03255
|
|
12044
Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M, Kinoshita M, Urakawa S, Iwagami Y, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Hirata M, Wada H, Mori M, Doki Y.
Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.
Cancer Sci.
2020
PubMed ID: 31799781
DOI: 10.1111/cas.14267
|
|
12462
Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S.
Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma
Carcinogenesis
2020
41(6):734-742
PubMed ID: 31665232
DOI: 10.1093/carcin/bgz179
|
|
12987
Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA.
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
Sci Adv
2020
PubMed ID: 32494639
DOI: 10.1126/sciadv.aaz3221
|
|
13005
Hsieh CH, Chu CY, Lin SE, Yang YSH, Chang HS, Yen Y.
TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma.
Cancers (Basel)
2020
PubMed ID: 32365487
DOI: 10.3390/cancers12051105
|
|
13336
Pan YR, Wu CE, Yeh CN.
ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.
Biomolecules
2020
PubMed ID: 33182492
DOI: 10.3390/biom10111529
|
|
13552
Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ.
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
Cancer Res Treat
2020
52(3):945-956
PubMed ID: 32311864
DOI: 10.4143/crt.2020.080
|
|
13897
Liu F, Zhu C, Gao P, Zheng S, Li C.
Ubiquitin-conjugating enzyme E2T regulates cell proliferation and migration in cholangiocarcinoma
Anticancer Drugs
2020
31(8):836-846
PubMed ID: 32796405
DOI: 10.1097/CAD.0000000000000955
|
|
13917
Tamai K, Nakamura-Shima M, Shibuya-Takahashi R, Kanno SI, Yasui A, Mochizuki M, Iwai W, Wakui Y, Abue M, Yamamoto K, Miura K, Mizuma M, Unno M, Kawamura S, Sato I, Yasuda J, Yamaguchi K,
BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma
Sci Rep
2020
10(1):21592
PubMed ID: 33299012
DOI: 10.1038/s41598-020-78539-0
|
|
16133
Fu W, Yu G, Liang J, Fan P, Dong K, Zhang B, Chen X, Zhu H, Chu L.
miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4
Front Oncol
2020
10:563486
PubMed ID: 33520692
DOI: 10.3389/fonc.2020.563486
|
|
11443
Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.
Invest New Drugs
2019
PubMed ID: 30778887
DOI: 10.1007/s10637-019-00741-3
|
|
11459
Farley AM, Braxton DR, Li J, Trounson K, Sakar-Dey S, Nayer B, Ikeda T, Lau KX, Hardikar W, Hasegawa K, Pera MF.
Antibodies to a CA 19-9 Related Antigen Complex Identify SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and Pancreatic Adenocarcinoma.
Sci Rep
2019
PubMed ID: 30814526
DOI: 10.1038/s41598-019-38988-8
|
|
11476
Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.
Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
Cell Death Dis
2019
PubMed ID: 30850583
DOI: 10.1038/s41419-019-1460-1
|
|
4244
Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Cancer Res Treat
2019
51(3):1167-1179
PubMed ID: 30514066
DOI: 10.4143/crt.2018.526
|
|
4245
Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.
Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Cancer Res Treat
2019
51(3):886-900
PubMed ID: 30282449
DOI: 10.4143/crt.2018.375
|
|
3737
Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.
Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
Cells
2019
8(9):1026
PubMed ID: 31484399
DOI: 10.3390/cells8091026
|
|
14816
Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
Cancer Discov
2019
9(8):1064-1079
PubMed ID: 31109923
DOI: 10.1158/2159-8290.CD-19-0182
|
|
10684
Kawashita Y, Morine Y, Saito Y, Takasu C, Ikemoto T, Iwahashi S, Teraoku H, Yoshikawa M, Imura S, Yagi T, Shimada M.
Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas.
J. Gastroenterol. Hepatol.
2018
33(7):1407-1412
PubMed ID: 29278438
DOI: 10.1111/jgh.14078
|
|
10740
Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, Fautrel A, Turlin B, Clément B, Dooley S, Sulpice L, Boudjema K, Coulouarn C.
A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma.
Hepatol Commun
2018
2:254-269
PubMed ID: 29507901
DOI: 10.1002/hep4.1142
|
|
10759
Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Jpn. J. Clin. Oncol.
2018
48:396-399
PubMed ID: 29474549
DOI: 10.1093/jjco/hyy011
|
|
11330
Komatsu N, Kajiya M, Motoike S, Takewaki M, Horikoshi S, Iwata T, Ouhara K, Takeda K, Matsuda S, Fujita T, Kurihara H.
Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.
Stem Cell Res Ther
2018
PubMed ID: 30526677
DOI: 10.1186/s13287-018-1085-9
|
|
11345
Kim J, Kim H, Lee JC, Kim JW, Paik WH, Lee SH, Hwang JH, Ryu JK, Kim YT.
Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
PLoS ONE
2018
PubMed ID: 30557411
DOI: 10.1371/journal.pone.0209104
|
|
4339
Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.
FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.
Cancer Sci.
2018
PubMed ID: 30302867
DOI: 10.1111/cas.13829
|
|
4347
Lin HY, Tey SL, Ho Y, Chin YT, Wang K, Whang-Peng J, Shih YJ, Chen YR, Yang YN, Chen YC, Liu YC, Tang HY, Yang YS.
Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway.
Mar Drugs
2018
PubMed ID: 30563284
DOI: 10.3390/md16120489
|
|
4486
Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB.
Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.
Hepatology
2018
68(3):949-963
PubMed ID: 29278425
DOI: 10.1002/hep.29764
|
|
14301
Wang J, Zhang ZG, Ding ZY, Dong W, Liang HF, Chu L, Zhang BX, Chen XP.
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
J Surg Res
2018
231:116-125
PubMed ID: 30278918
DOI: 10.1016/j.jss.2018.04.056
|
|
14913
Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
Dis Model Mech
2018
11(8):dmm03305
PubMed ID: 29666220
DOI: 10.1242/dmm.033050
|
|
10290
Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Mol. Carcinog.
2017
56:2146-2157
PubMed ID: 28467612
DOI: 10.1002/mc.22671
|
|
10312
Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.
Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.
Oncol. Rep.
2017
37:3660-3666
PubMed ID: 28498473
DOI: 10.3892/or.2017.5622
|
|
10363
Li P, Zhang L, Yang M, Qi M, Jin X, Han B.
Cul4B is a novel prognostic marker in cholangiocarcinoma.
Oncol Lett
2017
14:1265-1274
PubMed ID: 28808481
DOI: 10.3892/ol.2017.6297
|
|
10461
Nooron N, Ohba K, Takeda K, Shibahara S, Chiabchalard A.
Dysregulated Expression of MITF in Subsets of Hepatocellular Carcinoma and Cholangiocarcinoma.
Tohoku J. Exp. Med.
2017
242:291-302
PubMed ID: 28794318
DOI: 10.1620/tjem.242.291
|
|
5430
Li C, Imai M, Yamasaki M, Hasegawa S, Takahashi N.
Effects of Pre- and Post-Administration of Vitamin A on the Growth of Refractory Cancers in Xenograft Mice.
Biol Pharm Bull
2017
40(4):486-494
PubMed ID: 28100867
DOI: 10.1248/bpb.b16-00933
|
|
3727
Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Mol Oncol
2017
11(9):1130-1142
PubMed ID: 28544747
DOI: 10.1002/1878-0261.12078
|
|
5767
Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa Y, Okazaki S, Matsuura Y, Wakita T, Suzuki T.
Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.
Oncotarget
2017
8(33):53899-53915
PubMed ID: 28903311
DOI: 10.18632/oncotarget.19108
|
|
3923
Yoshitsugu OHNUKI, Takumi KONDO, Hiroshi KUROSAWA
ROCK INHIBITOR Y-27632 USED DURING CELL AGGREGATE FORMATION ADVERSELY AFFECTS THE EARLY CARDIAC DIFFERENTIATION OF HUMAN iPS CELLS
Tiss Cult Res Commun
2017
36:21–29
DOI: 10.11418/jtca.36.21
|
|
14252
Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification
Int J Oncol
2017
50(1):129-140.
PubMed ID: 27922671
DOI: 10.3892/ijo.2016.3786
|
|
14305
Hu MH, Chen LJ, Chen YL, Tsai MS, Shiau CW, Chao TI, Liu CY, Kao JH, Chen KF.
Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
Oncotarget
2017
8(39):65077-65089
PubMed ID: 29029413
DOI: 10.18632/oncotarget.17779
|
|
14568
Su Lin, Cheng He, Min-Fang Wang, Yin-Lian Wu, Jian Lin, Yi Liu, Yue-Yong Zhu
shRNA-mediated silencing of PKHD1 gene promotes proliferation, migration and invasion of human intrahepatic cholangiocarcinoma HuCCT-1 cells
Int J Clin Exp Pathol
2017
10(3):2496-2509
|
|
14636
Trinh SX, Nguyen HT, Saimuang K, Prachayasittikul V, Chan On W.
Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells
Asian Pac J Cancer Prev
2017
18(2):473-477
PubMed ID: 28345832
DOI: 10.22034/APJCP.2017.18.2.473
|
|
14652
Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H.
Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins
Oncotarget
2017
8(26):42159-42172
PubMed ID: 28178675
DOI: 10.18632/oncotarget.15020
|
|
7120
Agarinis C, Orsini V, Megel P, Abraham Y, Yang H, Mickanin C, Myer V, Bouwmeester T, Tchorz JS, Parker CN.
Activation of Yap-Directed Transcription by Knockdown of Conserved Cellular Functions.
J Biomol Screen
2016
21:269-76
PubMed ID: 26637552
DOI: 10.1177/1087057115617906
|
|
9516
Samatiwat P, Takeda K, Satarug S, Ohba K, Kukongviriyapan V, Shibahara S.
Induction of MITF expression in human cholangiocarcinoma cells and hepatocellular carcinoma cells by cyclopamine, an inhibitor of the Hedgehog signaling.
Biochem. Biophys. Res. Commun.
2016
470:144-9
PubMed ID: 26773496
DOI: 10.1016/j.bbrc.2016.01.010
|
|
9668
Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Src as a Therapeutic Target in Biliary Tract Cancer.
Mol. Cancer Ther.
2016
15:1515-24
PubMed ID: 27196758
DOI: 10.1158/1535-7163.MCT-16-0013
|
|
9700
Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.
Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
BMC Cancer
2016
16:322
PubMed ID: 27206490
DOI: 10.1186/s12885-016-2360-8
|
|
3735
Saha SK et al
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cancer Discov
2016
6(7):727-39
PubMed ID: 27231123
DOI: 10.1158/2159-8290.CD-15-1442
|
|
6235
Li C, Imai M, Matsuura T, Hasegawa S, Yamasaki M, Takahashi N.
Inhibitory Effects of Retinol Are Greater than Retinoic Acid on the Growth and Adhesion of Human Refractory Cancer Cells.
Biol Pharm Bull
2016
39(4):636-40
PubMed ID: 26822412
DOI: 10.1248/bpb.b15-00794
|
|
14116
Huyen NT, Prachayasittikul V, Chan-On W.
Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation
J Hepatobiliary Pancreat Sci
2016
23(7):397-405
PubMed ID: 27107220
DOI: 10.1002/jhbp.354
|
|
14138
Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Therapeutic implication of HER2 in advanced biliary tract cancer
Oncotarget
2016
7(36):58007-58021
PubMed ID: 27517322
DOI: 10.18632/oncotarget.11157
|
|
7424
Xu YF, Ge FJ, Han B, Yang XQ, Su H, Zhao AC, Zhao MH, Yang YB, Yang J.
High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
World J. Gastroenterol.
2015
21:3256-65
PubMed ID: 25805932
DOI: 10.3748/wjg.v21.i11.3256
|
|
7429
Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.
DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.
PLoS ONE
2015
10:e0120545
PubMed ID: 25799509
DOI: 10.1371/journal.pone.0120545
|
|
10114
Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E.
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
J Vasc Interv Radiol
2015
26:1874-78.e2
PubMed ID: 26596183
DOI: 10.1016/j.jvir.2015.06.032
|
|
3736
Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.
Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.
Mol Cancer Ther.
2015
14(9):1985-93
PubMed ID: 26141945
DOI: 10.1158/1535-7163.MCT-15-0069
|
|
13740
Guo S, Liu HD, Liu YF, Liu L, Sun Q, Cui XJ.
Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma
Tumour Biol
2015
36(1):353-64
PubMed ID: 25262276
DOI: 10.1007/s13277-014-2651-0
|
|
14311
Chan-On W, Huyen NT, Songtawee N, Suwanjang W, Prachayasittikul S, Prachayasittikul V.
Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells
Drug Des Devel Ther
2015
9:2033-47
PubMed ID: 25897210
DOI: 10.2147/DDDT.S79313
|
|
15124
Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM.
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Nat Commun
2015
6:6087
PubMed ID: 25608663
DOI: 10.1038/ncomms7087
|
|
15166
Yang H, Lu X, Liu Z, Chen L, Xu Y, Wang Y, Wei G, Chen Y.
FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells
Oncotarget
2015
6(8):6310-25
PubMed ID: 25749036
DOI: 10.18632/oncotarget.3355
|
|
14930
Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater
Int J Oncol
2014
44(4):1139-45
PubMed ID: 24481592
DOI: 10.3892/ijo.2014.2282
|
|
18681
Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM.
A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma
Hum Gene Ther
2013
24(5):554-64
PubMed ID: 23550539
DOI: 10.1089/hum.2012.136
|
|
19154
Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, Yi B, Zhang YJ.
miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells
Cell Physiol Biochem
2013
32(5):1331-41
PubMed ID: 24280681
DOI: 10.1159/000354531
|
|
12544
Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T.
Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma
Hepatol Res
2013
43(9):959-69
PubMed ID: 23369163
DOI: 10.1111/hepr.12047
|
|
19024
Imai M, Takahashi N.
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma
Bioorg Med Chem
2012
20(8):2520-6
PubMed ID: 22440084
DOI: 10.1016/j.bmc.2012.02.060
|
|
12868
Yoshida M, Takimoto R, Murase K, Sato Y, Hirakawa M, Tamura F, Sato T, Iyama S, Osuga T, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J.
Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach
PLoS One
2012
7(7):e39545
PubMed ID: 22808043
DOI: 10.1371/journal.pone.0039545
|
|
14852
Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
Gastroenterology
2012
142(4):1021-1031.e15
PubMed ID: 22178589
DOI: 10.1053/j.gastro.2011.12.005
|
|
7767
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.
Br. J. Cancer
2011
105:131-8
PubMed ID: 21673683
DOI: 10.1038/bjc.2011.199
|
|
7898
Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S, Shimada M.
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
J. Med. Invest.
2011
58:106-9
PubMed ID: 21372494
DOI: 10.2152/jmi.58.106
|
|
7971
Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.
Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis.
Cancer Sci.
2011
102:1045-51
PubMed ID: 21272158
DOI: 10.1111/j.1349-7006.2011.01886.x
|
|
13665
Kamigaki M, Sasaki T, Serikawa M, Inoue M, Kobayashi K, Itsuki H, Minami T, Yukutake M, Okazaki A, Ishigaki T, Ishii Y, Kosaka K, Chayama K.
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells
Int J Oncol
2011
39(3):561-8
PubMed ID: 21687941
DOI: 10.3892/ijo.2011.1087
|
|
13715
Kudo C, Yamakoshi H, Sato A, Nanjo H, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.
Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo
BMC Pharmacol
2011
11:4
PubMed ID: 21619659
DOI: 10.1186/1471-2210-11-4
|
|
15724
Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H.
E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma
Br J Cancer
2011
105(12):1885-93
PubMed ID: 22068819
DOI: 10.1038/bjc.2011.452
|
|
16146
Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Saito Y.
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis
Oncol Rep
2011
26(5):1057-62
PubMed ID: 21805043
DOI: 10.3892/or.2011.1407
|
|
19310
Takayama Y, Kokuryo T, Yokoyama Y, Ito S, Nagino M, Hamaguchi M, Senga T.
Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis
Cancer Lett
2010
296(1):27-34
PubMed ID: 20381954
DOI: 10.1016/j.canlet.2010.03.011
|
|
13667
Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment
Cancer Sci
2010
101(4):882-8
PubMed ID: 20088962
DOI: 10.1111/j.1349-7006.2009.01462.x
|
|
18737
Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.
Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues
J Proteome Res
2009
8(8):4092-103
PubMed ID: 19569727
DOI: 10.1021/pr900468k
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
|
18311
Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y, Noda A, Nakamura Y, Nishimura S, Tsuji A.
Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter
J Nucl Med
2008
49(4):615-22
PubMed ID: 18344442
DOI: 10.2967/jnumed.107.048231
|
|
15602
Guleng B, Tateishi K, Ohta M, Asaoka Y, Jazag A, Lin LJ, Tanaka Y, Tada M, Seto M, Kanai F, Kawabe T, Omata M.
Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity
J Gastroenterol
2006
41(12):1238-9
PubMed ID: 17287906
DOI: 10.1007/s00535-006-1955-2
|
Back
Top
CELL BANK Website
